Contraline is developing ADAM™, a long-lasting, non-hormonal implant for male contraception that functions similarly to an IUD. This device addresses the need for a reliable and reversible contraceptive option for men, eliminating the anxiety and inconvenience associated with current methods.
Funding
$35.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current male contraceptive options are limited to condoms or vasectomy, with a lack of long-lasting, reversible, and hormone-free alternatives. This gap leaves many men without convenient or appealing choices for family planning.
Solution
Contraline is developing ADAM™, a long-lasting, non-hormonal male contraceptive implant designed to function similarly to an IUD. The device is placed in the vas deferens to block sperm flow, providing a reversible method of contraception. ADAM™ aims to offer men a reliable and convenient option that eliminates the anxiety and inconvenience associated with existing methods, without the use of hormones. Clinical trials for ADAM™ have begun, marking a significant step toward expanding male contraceptive choices.
Target Audience
The primary target audience is men seeking a long-lasting, reversible, and non-hormonal alternative to condoms or vasectomy for contraception.
Features
- Non-hormonal mechanism of action, avoiding hormonal side effects
- Long-lasting contraceptive effect, reducing the need for frequent action
- Reversible design, allowing men to restore fertility if desired
- Implantable device placed in the vas deferens
- Designed to block sperm flow